Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zylet vs Tobradex in BKC
NCT01028027Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Oct 2009
- Primary completion
- Feb 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of loteprednol etabonate ophthalmic gel 0.38% in blepharokeratoconjunctivitis (BKC) (2 arms), sponsored by Bausch + Lomb. Primary endpoint: Signs and Symptoms Composite Score at Day 15. Started Oct 2009; status: completed.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
03
Conditions
blepharokeratoconjunctivitis (BKC)
Beyond the preview
Go deeper on NCT01028027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01028027.